Zanubrutinib as Third-Line and Beyond Therapy for FL
Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.
Source: onclive.com
Augment Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Augment Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Augment Trial Today - Breaking & Trending Today